Page 39 - product-manual

TM/MC TM/MC
PHARMACOLOGICAL ACTIVITIES - TOXICOLOGY - DRUG INTERACTIONS

Boswellia serrata (Indian Frankincense)

Boswellic acids, the major constituent of Gummi Boswellii, are thought to contribute to most of
the herb’s pharmacological activities. Animal studies and clinical trials support the potential of
Gummi Boswellii for the treatment of a variety of inflammatory diseases such as inflammatory
bowel disease, rheumatoid arthritis, osteoarthritis and asthma. In inflammatory response, the
molecular targets of Gummi Boswellii are inhibition of microsomal prostaglandin E
synthase-1, serine protease cathepsin G, and suppression of leukotriene formation via inhibition of
5-lipoxygenase which are attributed to boswellic acids such as β-boswellic acid, 11-keto-β-
boswellic acid and acetyl-11-keto-β-boswellic acid (Safayi et al., 1997; Siemoneit et al., 2009;
Kunnumakkara et al., 2009; Abdel-Tawab et al., 2011). In an open multi-centre veterinary clinical
trial in dogs with osteoarthritis and degenerative conditions, dietary support with Gummi
Boswellii demonstrated statistically significant reduction of severity and resolution of clinical
signs such as intermittent lameness, local pain and stiff gait (Reichling et al., 2004).

Note:
Boswellia serrata is also an ingredient in Articulare-VM™. In inflammatory response, the molecular targets of Gummi Boswellii are
inhibition of microsomal prostaglandin E synthase-1, serine protease cathepsin G, and suppression of leukotriene formation.

Toxicity for Gummi Boswellii has not been documented in dogs and cats when administered orally in therapeutic
TOXICOLOGY established at >2 g/kg of body weight (Singh & Atal, 1986). 50
doses. In toxicity studies of Gummi Boswellii extract in rats and mice, the oral and intraperitoneal LD has been

Equivalent toxic dose in 20 kg dog: >40 g PO and IP of Gummi Boswellii extract.
>10 g PO and IP of Gummi Boswellii extract.
Equivalent toxic dose in 5 kg cat:

DRUG Validated interactions studies do not exist for Gummi Boswellii preparations. Clinical interactions
INTERACTIONS with other drugs have not been reported.

4 | Antitis-VM TM